These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12365826)

  • 1. NMDA receptor antagonists and glycine site NMDA antagonists.
    Madden K
    Curr Med Res Opin; 2002; 18 Suppl 2():s27-31. PubMed ID: 12365826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions.
    Jansen M; Dannhardt G
    Eur J Med Chem; 2003; 38(7-8):661-70. PubMed ID: 12932897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with excitatory amino acid antagonist drugs.
    Muir KW; Lees KR
    Stroke; 1995 Mar; 26(3):503-13. PubMed ID: 7886734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of glycine site NMDA receptor antagonists to protect against L-2-chloropropionic acid-induced neurotoxicity highlights the uniqueness of cerebellar NMDA receptors.
    Widdowson PS; Gyte AJ; Upton R; Wyatt I
    Brain Res; 1996 Nov; 738(2):236-42. PubMed ID: 8955518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NMDA receptor complex: a long and winding road to therapeutics.
    Wood PL
    IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycine/NMDA receptor antagonists as potential CNS therapeutic agents: ACEA-1021 and related compounds.
    Cai SX
    Curr Top Med Chem; 2006; 6(7):651-62. PubMed ID: 16719807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?
    Ikonomidou C; Turski L
    Lancet Neurol; 2002 Oct; 1(6):383-6. PubMed ID: 12849400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competitive Gly/NMDA receptor antagonists.
    Catarzi D; Colotta V; Varano F
    Curr Top Med Chem; 2006; 6(8):809-21. PubMed ID: 16719819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel glycineB antagonists show neuroprotective activity in vivo.
    Wenk GL; Baker LM; Hauss-Wegrzyniak B; Danysz W; Stoehr JD
    Amino Acids; 1998; 14(1-3):223-6. PubMed ID: 9871465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing conditions significantly attenuate the neuroprotective efficacy of competitive, but not other NMDA receptor antagonists in vitro.
    Pringle AK; Self J; Eshak M; Iannotti F
    Eur J Neurosci; 2000 Nov; 12(11):3833-42. PubMed ID: 11069578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications.
    Dannhardt G; Kohl BK
    Curr Med Chem; 1998 Aug; 5(4):253-63. PubMed ID: 9668194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GlycineB antagonists as potential therapeutic agents. Previous hopes and present reality.
    Danysz W; Parsons CG; Karcz-Kubicha M; Schwaier A; Popik P; Wedzony K; Lazarewicz J; Quack G
    Amino Acids; 1998; 14(1-3):235-9. PubMed ID: 9871467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rise and fall of NMDA antagonists for ischemic stroke.
    Hoyte L; Barber PA; Buchan AM; Hill MD
    Curr Mol Med; 2004 Mar; 4(2):131-6. PubMed ID: 15032709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerestat and other NMDA antagonists in ischemic stroke.
    Lees KR
    Neurology; 1997 Nov; 49(5 Suppl 4):S66-9. PubMed ID: 9371155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease--comparison with uncompetitive N-methyl-D-aspartate receptor antagonist.
    Karcz-Kubicha M; Lorenz B; Danysz W
    Neuropharmacology; 1999 Jan; 38(1):109-19. PubMed ID: 10193902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it time to conclude that NMDA antagonists have failed?
    Roesler R; Quevedo J; Schröder N
    Lancet Neurol; 2003 Jan; 2(1):13; discussion 13. PubMed ID: 12849294
    [No Abstract]   [Full Text] [Related]  

  • 18. Protective use of N-methyl-D-aspartate receptor antagonists as a spinoplegia against excitatory amino acid neurotoxicity.
    Cho Y; Ueda T; Mori A; Shimizu H; Haga Y; Yozu R
    J Vasc Surg; 2005 Oct; 42(4):765-71. PubMed ID: 16242566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor mediates xenon neuroprotection against hypoxia-ischemia.
    Banks P; Franks NP; Dickinson R
    Anesthesiology; 2010 Mar; 112(3):614-22. PubMed ID: 20124979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of glycine site antagonists of the NMDA receptor in global cerebral ischaemia.
    Hicks CA; Ward MA; Ragumoorthy N; Ambler SJ; Dell CP; Dobson D; O'Neill MJ
    Brain Res; 1999 Feb; 819(1-2):65-74. PubMed ID: 10082862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.